

Status: Currently Official on 16-Feb-2025
Official Date: Official Prior to 2013
Document Type: USP Monographs
DocId: GUID-DC723633-7329-4A00-A52E-AFE0DDF2B7DC_1_en-US
DOI: https://doi.org/10.31003/USPNF_M62520_01_01
DOI Ref: qy760

© 2025 USPC
Do not distribute

Pergolide Tablets

» Pergolide Tablets contain an amount of Pergolide Mesylate equivalent to not less than 90.0 percent and not more than 110.0 percent of the labeled amount of pergolide ($C_{19}H_{26}N_2S$).

Packaging and storage—Preserve in tight, light-resistant containers.

USP REFERENCE STANDARDS (11)—

[USP Pergolide Mesylate RS](#)

[USP Pergolide Sulfoxide RS](#)

(8β)-8-[(Methylsulfinyl)methyl]-6-propyl-*D*-ergoline.

THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST (201)—

Adsorbent: 0.25-mm layer of binder-free silica gel.

Test solution—Transfer a number of Tablets, equivalent to 1 mg of pergolide, to a separator containing 20 mL of methylene chloride and 10 mL of 0.1 N sodium hydroxide. Shake until the Tablets have disintegrated, allow the layers to separate, and drain the methylene chloride layer through a small funnel containing about 1 g of anhydrous sodium sulfate, collecting the filtrate in a suitable stoppered vessel. Wash the sodium sulfate with a few mL of methylene chloride, adding these washes to the filtrate, and evaporate to dryness under a stream of nitrogen. Redissolve the residue in 2 mL of a mixture of methylene chloride and methanol (1:1).

Standard solution: 0.65 mg per mL, in a mixture of methylene chloride and methanol (1:1).

Application volume: 20 µL.

Developing solvent system: a mixture of chloroform, methanol, and ethyl acetate (8:1:1). Allow the plate to equilibrate for about 10 minutes in the developing chamber prior to development.

Procedure—Proceed as directed in the chapter. Place the plate in a chamber containing iodine vapors, and locate the spots.

DISSOLUTION (711)—

Medium: simulated gastric fluid TS (without enzymes) containing 20 µg of L-cysteine per mL; 500 mL.

Apparatus 2: 50 rpm.

Time: 30 minutes.

Determine the amount of $C_{19}H_{26}N_2S$ dissolved by employing the following method.

Mobile phase—Prepare a filtered and degassed mixture of acetonitrile, water, and triethylamine, (21:19:0.08). Adjust with phosphoric acid to a pH of 5.0. Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

Triethylamine phosphate suspension—Add 1.0 mL of triethylamine to 500 mL of acetonitrile, mix, and adjust with phosphoric acid to a pH of 5.0. A white precipitate will form. Stir continuously during use.

Resolution solution—Prepare a solution of [USP Pergolide Mesylate RS](#) and [USP Pergolide Sulfoxide RS](#) containing a known amount of each equivalent to the labeled amount of pergolide in each 500 mL of *Medium*.

Standard solution—Transfer about 16 mg of [USP Pergolide Mesylate RS](#), accurately weighed, to a 250-mL volumetric flask, dissolve in 10.0 mL of methanol, dilute with *Medium* to volume, and mix. Dilute this solution quantitatively and stepwise with *Medium* to obtain a solution having a known concentration equivalent to the labeled amount of pergolide in each 500 mL.

Chromatographic system (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a fluorometer set to an excitation wavelength of 224 nm and an emission wavelength of 350 nm and with a 4.6-mm × 15-cm column that contains base-deactivated packing L10. The flow rate is about 2 mL per minute. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between pergolide sulfoxide and pergolide is not less than 1.0. Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the relative standard deviation for replicate injections, determined from the pergolide peak, is not more than 2.0%.

Procedure—Immediately before injection, pipet 2.0 mL of *Triethylamine phosphate suspension*, continuously stirred, into a suitable container containing 5.0 mL of the solution for injection, and mix to obtain a clear solution. Separately inject equal volumes (about 200 µL) of the *Standard solution* and filtered portions of the solutions under test into the chromatograph, record the chromatograms, and measure the areas

for the major peaks. Calculate the amount, in mg, of pergolide ($C_{19}H_{26}N_2S$) dissolved by the formula:

$$500C(314.50/410.60)(r_U/r_S)$$

in which C is the concentration, in μg per mL, of [USP Pergolide Mesylate RS](#) in the *Standard solution*; 314.50 and 410.60 are the molecular weights of pergolide and pergolide mesylate, respectively; and r_U and r_S are the peak areas obtained from the solution under test and the *Standard solution*, respectively.

Tolerances—Not less than 75% (Q) of the labeled amount of $C_{19}H_{26}N_2S$ is dissolved in 30 minutes.

UNIFORMITY OF DOSAGE UNITS (905): meet the requirements.

Chromatographic purity—

Mobile phase, System suitability solution, Standard preparation, and Chromatographic system—Proceed as directed in the Assay.

Diluted standard preparation—Transfer 3.0 mL of the *Standard preparation* to a 50-mL volumetric flask. Dilute with *Mobile phase* to volume, and mix.

Test preparation—Use the Assay preparation.

Procedure—Separately inject equal volumes (about 100 μL) of the *Diluted standard preparation* and the *Test preparation* into the chromatograph, and measure all of the peak responses. Calculate the percentage of each impurity in the Tablets by the formula:

$$20C(314.50/410.60)(r_I/r_S)$$

in which C is the concentration, in μg per mL, of [USP Pergolide Mesylate RS](#) in the *Diluted standard preparation*; 314.50 and 410.60 are the molecular weights of pergolide and pergolide mesylate, respectively; r_I is the peak response of the individual impurity obtained from the *Test preparation*; and r_S is the peak response of pergolide obtained from the *Diluted standard preparation*: not more than 6.0% of pergolide sulfoxide is found; not more than 0.5% of any individual impurity, excluding pergolide sulfoxide, is found; and not more than 1.0% of total impurities, excluding pergolide sulfoxide, is found.

Assay—

Mobile phase—Prepare a solution of 0.038 M sodium 1-octanesulfonate containing 0.0077 mg of methionine per mL and 2.45 mL of glacial acetic acid per L. Adjust with 5 N sodium hydroxide to a pH of 4.1. Prepare a filtered and degassed mixture of this solution and acetonitrile (65:35). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

System suitability solution—Prepare a solution of [USP Pergolide Mesylate RS](#) and [USP Pergolide Sulfoxide RS](#) in *Mobile phase* having a known concentration of about 6.5 μg per mL of pergolide mesylate and 0.1 μg per mL of pergolide sulfoxide.

Standard preparation—Dissolve an accurately weighed quantity of [USP Pergolide Mesylate RS](#) in *Mobile phase*, and dilute quantitatively and stepwise with *Mobile phase* to obtain a solution having a known concentration of about 6.5 μg per mL.

Assay preparation—Place 20 whole Tablets into a suitable stoppered container, add *Mobile phase*, shake and sonicate until the Tablets have dissolved, and quantitatively dilute to obtain a solution containing about 5 μg per mL of pergolide.

Chromatographic system (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a fluorometer set to an excitation wavelength of 280 nm and an emission wavelength of 335 nm and with a 4.6-mm \times 7.5-cm column that contains base-deactivated packing L7. The flow rate is about 1.5 mL per minute. The column temperature is maintained at 35°. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the resolution, R, between pergolide sulfoxide and pergolide is not less than 12.0; and the relative standard deviation for replicate injections is not more than 2.0%.

Procedure—Separately inject equal volumes (about 100 μL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, and measure the responses for the major peaks. Calculate the quantity, in mg, of pergolide ($C_{19}H_{26}N_2S$) in the portion of Tablets taken by the formula:

$$0.001C(314.50/410.60)(r_U/r_S)$$

in which C is the concentration, in μg per mL, of [USP Pergolide Mesylate RS](#) in the *Standard preparation*; 314.50 and 410.60 are the molecular weights of pergolide and pergolide mesylate, respectively; and r_U and r_S are the peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PERGOLIDE TABLETS	Documentary Standards Support	SM32020 Small Molecules 3

Topic/Question	Contact	Expert Committee
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: GUID-DC723633-7329-4A00-A52E-AFE0DDF2B7DC_1_en-US
DOI: https://doi.org/10.31003/USPNF_M62520_01_01
DOI ref: [gy760](#)

OFFICIAL